The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Break Apart Probe
- Order Number
- Package Size
- 100 µl
In 2008 the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. Many of these cases present as a myeloproliferative neoplasm, usually with eosinophilia.
Myeloid neoplasms (MPNs) with rearrangement of PDGFRB are phenotypically and genotypically diverse. The fusion genes involving PDGFRB described to date have been associated with cytogenetically detectable translocations. MPNs associated with rearrangement of PDGFRB are responsive to Imatinib.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
Two green-orange fusion signals (2GO) representing the two normal PDGFRB loci.
Aberrant Cell (typical results):
One green-orange fusion signal (1GO) and one green (1G), one orange (1O) indicating a chromosome break in the PDGFRB locus.
- Wlodarska et al (1997) Blood 89:1716-1722
- Apperley et al (2002) N Engl J Med 347:481-487
- Wilkinson et al (2003) Blood 102:4187-4190